VolitionRx Limited (NYSE American: VNRX) has announced the submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The assay achieved 97% specificity and identified 86% of lymphoma cases, marking a significant step forward in the development of a blood-based liquid biopsy test for feline cancer. The company believes this technology addresses a substantial unmet need in veterinary medicine, where non-invasive diagnostic tools for cancer are limited.
The study results suggest that the Nu.Q Vet Feline assay could provide a valuable screening tool for veterinarians, enabling earlier detection of lymphoma, a common cancer in cats. Early diagnosis is critical for improving treatment outcomes and quality of life for affected animals. VolitionRx is working toward commercializing the product and expanding its presence in the growing companion animal oncology market. The company sees this as a significant commercial opportunity with potential milestone payments and future revenue generation.
VolitionRx expects that publication of the study in a peer-reviewed journal will unlock a contractual milestone payment of $5 million. This payment would provide capital to support further development and commercialization efforts. The company is also exploring the application of its Nu.Q technology in other veterinary and human diseases.
The press release announcing the submission is available at https://ibn.fm/ARsEY. VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it develops and commercializes simple, cost-effective blood tests for early detection and monitoring of diseases, including cancers and sepsis. The company's research and development activities are centered in Belgium, with additional offices in the U.S. and London.
This development is important not only for veterinary medicine but also as a proof of concept for VolitionRx's Nu.Q technology platform, which may have broader applications in human oncology and other disease areas. The high specificity and sensitivity demonstrated in this study suggest the potential for reliable non-invasive cancer screening in animals, which could lead to improved veterinary care and owner peace of mind.
For further information about VolitionRx, visit www.Volition.com. The contents of the company's website are not incorporated by reference into this document.
